Compare CUZ & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CUZ | GH |
|---|---|---|
| Founded | 1958 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 14.1B |
| IPO Year | N/A | 2018 |
| Metric | CUZ | GH |
|---|---|---|
| Price | $24.93 | $98.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 21 |
| Target Price | $31.10 | ★ $95.29 |
| AVG Volume (30 Days) | 1.3M | ★ 2.3M |
| Earning Date | 02-05-2026 | 10-29-2025 |
| Dividend Yield | ★ 5.11% | N/A |
| EPS Growth | ★ 3.48 | N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $955,949,000.00 | $902,569,000.00 |
| Revenue This Year | $14.95 | $34.72 |
| Revenue Next Year | $2.68 | $26.46 |
| P/E Ratio | $72.21 | ★ N/A |
| Revenue Growth | 15.46 | ★ 30.38 |
| 52 Week Low | $24.07 | $29.91 |
| 52 Week High | $31.59 | $112.43 |
| Indicator | CUZ | GH |
|---|---|---|
| Relative Strength Index (RSI) | 43.04 | 48.59 |
| Support Level | $24.90 | $96.28 |
| Resistance Level | $25.52 | $105.01 |
| Average True Range (ATR) | 0.51 | 4.13 |
| MACD | 0.05 | -1.83 |
| Stochastic Oscillator | 46.63 | 14.27 |
Cousins Properties Inc is a real estate investment trust principally involved in the ownership, management, and development of properties in the Southern United States. Cousins Properties' real estate portfolio mainly comprises offices and mixed-use developments that encompass both apartment and retail space. Offices make up the vast majority of the portfolio in terms of total square footage. The segments operates in following geographical areas: Atlanta, Austin, Charlotte, Dallas, Phoenix, Tampa, and other markets. The company derives nearly all of its revenue in the form of rental income from its properties, the majority of which comes from its office locations. A diverse set of tenants in the cities of Houston and Atlanta represent the company's key markets.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.